What The Expanded CMS Guidelines Mean for your Medicare Patients
May 15, 2023
Real-time real talk is intended for healthcare professionals in the US.
Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individualresults may vary – nothing you hear on this podcast should be considered medical advice. All claims are supportedby clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 UserGuide. For product-related questions, please refer to the instructions for use. For complete safety information, goto dexcom.com/safety-information.Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility.The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucosemonitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has nolimitations for use in pregnancy.About New Expanded Medicare GuidelinesAbout Hello DexcomDexcom Provider websiteAbout Medicaid coverageDexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7.Data from collaborator devices and products must be verified by those collaborator devices and products. Usersshould confirm data and connections with their collaborator devices and products.A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends.CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatmentdecisions.Brief Safety StatementBRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and itscomponents according to the instructions for use provided with your device and available athttps://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings,precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low bloodglucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result ininjury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to makediabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medicalemergency.Dexcom Clarity Safety InformationThe web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals toassist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historicalCGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGMdevices with data interface capabilities. Caution: The software does not provide any medical advice and should notbe used for that purpose. Home users must consult a healthcare professional before making any medicalinterpretation and therapy adjustments from the information in the software. Caution: Healthcare professionalsshould use information in the software in conjunction with other clinical information available to them. Caution:Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional.Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S.,and may be registered in other countries.References1. Dexcom G7 User Guide2. Martens T, Beck RW, Bailey R, et al. Effect of Continuous Glucose Monitoring on Glycemic Control inPatients With Type 2 Diabetes Treated With Basal Insulin: A Randomized ClinicalTrial. JAMA. 2021;325(22):2262–2272. doi:10.1001/jama.2021.74443. Aleppo G, et al. The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2Diabetes Treated With Basal Insulin. Diabetes Care. 2021 Dec;44(12):2729-2737. doi: 10.2337/dc21-1304
Real-time real talk is intended for healthcare professionals in the US.
Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. About New Expanded Medicare Guidelines About Hello Dexcom Dexcom Provider website About Medicaid coverage Dexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7. Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products. A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatment decisions. Brief Safety Statement BRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom Clarity Safety Information The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. References 1. Dexcom G7 User Guide 2. Martens T, Beck RW, Bailey R, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. JAMA. 2021;325(22):2262–2272. doi:10.1001/jama.2021.7444 3. Aleppo G, et al. The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. Diabetes Care. 2021 Dec;44(12):2729-2737. doi: 10.2337/dc21-1304. Epub 2021 Sep 29. PMID: 34588210; PMCID: PMC8669539. 4. Psavko S, Katz N, Mirchi T, Green CR. Usability and teachability of continuous glucose monitoring devices in older adults and diabetes educators: a task analysis and ease of use survey. JMIR Hum Factors. 2022 Nov 8. doi: 10.2196/42057 5. International Hypoglycemia Study Group. Diabetes Care. 2015;38:1583-1591. 6. Boureau AS, et al. Nocturnal hypoglycemia is underdiagnosed in older people with insulin-treated type 2 diabetes: The HYPOAGE observational study. J Am Geriatr Soc. 2023;1–13. DOI: 10.1111/jgs.18341. 7. Acciaroli G, Welsh JB, Akturk HK. Mitigation of Rebound Hyperglycemia With Real-Time Continuous Glucose Monitoring Data and Predictive Alerts. J Diabetes Sci Technol. 2022 May;16(3):677-682. doi: 10.1177/1932296820982584. Epub 2021 Jan 5. PMID: 33401946; PMCID: PMC9294577. 8. Puhr S, Derdzinski M, Welsh JB, Parker AS, Walker T, Price DA. Real-World Hypoglycemia Avoidance with a Continuous Glucose Monitoring System's Predictive Low Glucose Alert. Diabetes Technol Ther. 2019 Apr;21(4):155-158. doi: 10.1089/dia.2018.0359. Epub 2019 Mar 22. PMID: 30896290; PMCID: PMC6477579. 9. Shichun Bao, Ryan Bailey, Peter Calhoun, and Roy W. Beck.Effectiveness of Continuous Glucose Monitoring in Older Adults with Type 2 Diabetes Treated with Basal Insulin.Diabetes Technology & Therapeutics.May 2022.299-306.http://doi.org/10.1089/dia.2021.0494 10. By 2023, there had been 52 million ULS alerts from Dexcom CGM systems, and 11 million of those occurred during the night. Dexcom data on file, 2023.
Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. About New Expanded Medicare Guidelines About Hello Dexcom Dexcom Provider website About Medicaid coverage Dexcom’s partners are working to integrate insulin pumps, insulin pens, and digital health apps with Dexcom G7. Data from collaborator devices and products must be verified by those collaborator devices and products. Users should confirm data and connections with their collaborator devices and products. A separate Follow app and internet connection are required to follow CGM users’ glucose readings and trends. CGM users should always confirm glucose readings on the Dexcom G7 app or receiver before making treatment decisions. Brief Safety Statement BRIEF SAFETY STATEMENT: Failure to use the Dexcom G7 Continuous Glucose Monitoring System (G7) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose0 or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G7 do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom Clarity Safety Information The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. References 1. Dexcom G7 User Guide 2. Martens T, Beck RW, Bailey R, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. JAMA. 2021;325(22):2262–2272. doi:10.1001/jama.2021.7444 3. Aleppo G, et al. The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. Diabetes Care. 2021 Dec;44(12):2729-2737. doi: 10.2337/dc21-1304. Epub 2021 Sep 29. PMID: 34588210; PMCID: PMC8669539. 4. Psavko S, Katz N, Mirchi T, Green CR. Usability and teachability of continuous glucose monitoring devices in older adults and diabetes educators: a task analysis and ease of use survey. JMIR Hum Factors. 2022 Nov 8. doi: 10.2196/42057 5. International Hypoglycemia Study Group. Diabetes Care. 2015;38:1583-1591. 6. Boureau AS, et al. Nocturnal hypoglycemia is underdiagnosed in older people with insulin-treated type 2 diabetes: The HYPOAGE observational study. J Am Geriatr Soc. 2023;1–13. DOI: 10.1111/jgs.18341. 7. Acciaroli G, Welsh JB, Akturk HK. Mitigation of Rebound Hyperglycemia With Real-Time Continuous Glucose Monitoring Data and Predictive Alerts. J Diabetes Sci Technol. 2022 May;16(3):677-682. doi: 10.1177/1932296820982584. Epub 2021 Jan 5. PMID: 33401946; PMCID: PMC9294577. 8. Puhr S, Derdzinski M, Welsh JB, Parker AS, Walker T, Price DA. Real-World Hypoglycemia Avoidance with a Continuous Glucose Monitoring System's Predictive Low Glucose Alert. Diabetes Technol Ther. 2019 Apr;21(4):155-158. doi: 10.1089/dia.2018.0359. Epub 2019 Mar 22. PMID: 30896290; PMCID: PMC6477579. 9. Shichun Bao, Ryan Bailey, Peter Calhoun, and Roy W. Beck.Effectiveness of Continuous Glucose Monitoring in Older Adults with Type 2 Diabetes Treated with Basal Insulin.Diabetes Technology & Therapeutics.May 2022.299-306.http://doi.org/10.1089/dia.2021.0494 10. By 2023, there had been 52 million ULS alerts from Dexcom CGM systems, and 11 million of those occurred during the night. Dexcom data on file, 2023.